publications (Clinical Papers, Review articles, Case reports, Letters, Editorials)

     
1

S Sundar, P Symonds. Cancer patients' anxiety. The Lancet. 2003. 361: 1746 - 47.

 
2

S Sundar, P Lawton. International register of trial acronyms. The Lancet. 2004. 363:171

 
3

S Sundar, MP Decatris, DM Kumar. Cure without complications: A population based analysis of treatment intensity and survival in testicular Germ Cell tumours. Clinical Oncology. 2003. Vol 15 (2): 84-85.

 
4

RA Sharma, MP Decatris, S Santhanam, R Roy, AE Osman, CB Clarke, S Khanna, KJ O'Byrne . Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. Cancer Chemother Pharmacol. 2003;52(5):367-70.

 
5

S Sundar, P Symonds, C Deehan. The Tolerance of Pelvic organs to Radiation treatment for Carcinoma of Cervix. Clinical Oncology. 2003.15(5):240-7

 
6

S Sundar, RP Symonds. Diagnostic Radiology for Radiotherapist: The case for structured training in cross-sectional imaging (CT and MRI). Clinical Oncology. 2002. Vol 14 (5): 413-414

 
7

S Santhanam, KJ O'Byrne. Antioestrogens and breast cancer. Journal of the British Menopause Society.2001: Vol 7(1): 21-26

 
8

 S Sundar, M Decatris, KJ O' Byrne. Management of endocrine resistant breast cancer. Journal of the British Menopause Society.2004 Mar;10(1):16-23.

 
9

S Sundar, SY Chan. Cholestatic jaundice and pseudomembranous colitis following combination therapy with doxorubicin and docetaxel. Anti-Cancer Drugs.2003.14 (4): 327

 
10

S Santhanam, M Decatris, KJ O' Byrne. Potential of Interferon-alpha in Solid Tumours: Part-2. BioDrugs. 2002, Vol. 16(5):349-72.

 
11

M Decatris, S Santhanam, KJ O' Byrne. Potential of Interferon-alpha  in Solid Tumours: Part-1. BioDrugs. 2002, Vol. 16, (4): 261-281.

 
12

M Decatris, S Sundar, KJ O' Byrne. Platinum based Chemotherapy in metastatic breast cancer: Current Status. Cancer Treat Rev. 2004;30(1):53-81

 
13

KJ O' Byrne, S Sundar. Role of anthracyclines in Ovarian cancer. MIMS Advances: Ovarian cancer. 2003. May. 5-6.

 
14

DM Kumar, S Sundar, S Vasanthan. A Case of Paclitaxel induced Pancreatitis. Clinical Oncology. 2003. Vol 15 (1):35

 
15

Muthu Kumar D, Symonds RP, Sundar S, Ibrahim K, Savelyich BS, Miller E.  Information needs of Asian and White British cancer patients and their families in Leicestershire: a cross-sectional survey. Br J Cancer. 2004 Apr 19;90(8):1474-8.      

 
16

S Sundar, RP Symonds, MP Decartis, DM Kumar, A Osman, S Vasanthan,KJ O'Byrne. Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum based therapy. Gynecologic Oncology.2004; 94(2):502-8.     

 
17

M.P. Decatris, S. Sundar and K.J. O'Byrne. Platinum-based Chemotherapy in Metastatic Breast Cancer: The Leicester (UK) Experience. Clinical Oncology. 2005: Vol 17 (4): 249-257    

 
18

S.Sundar, P Symonds, C Deehan. Radiotherapy to patients with artificial cardiac pacemakers. Cancer Treat Rev. 2005;31(6):474-86.    

 
19

S.Sundar, K.J. O'Byrne. CA-125 criteria for response evaluation in Ovarian Cancer. Gynecol Oncol. 2005;98(3):520-1.    

 
20

A Dhadda, D Lakshmanan, M Sokal, S Sundar . Age does not influence acute toxicity during radiotherapy dose escalation for prostate cancer. Clin Oncol (R Coll Radiol). 2006 Aug;18(6):506-7.   

 
21

M. Griffin, A. Dhadda, A. Wade, M. Sokal, S. Sundar. Male Cancer Patients’ Attitudes towards Female Health Professionals during Urological Consultations. Clin Oncol (R Coll Radiol). 2006 Sep;18(7):572-3.    

 
22

Smellie WS, Forth J, Sundar S, Kalu E, McNulty CA, Sherriff E, Watson ID, Croucher C, Reynolds TM, Carey PJ. Best Practice in Primary Care Pathology: review 4. Should PSA should be measured in asymptomatic men?. What action should be taken in a patient with a raised PSA?. How often PSA should be measured in patients who have been diagnosed as suffering from prostate cancer?. J Clin Pathol. 2006 Sep;59(9):893-902.     

 
23

Chaudhuri A, Griffin M, Sundar S. Utility of regular serum biochemistry and midstream urine cultures in men undergoing three-dimensional conformal pelvic radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol). 2007 Mar;19(2):162.     

 
24

Joynson CP, Sundar S, Symonds P. Anaemia is associated with poor overall survival but not with inferior local control in patients with muscle invasive bladder carcinoma treated by radical external beam radiotherapy. A retrospective study. Clin Oncol (R Coll Radiol). 2006 Dec;18(10):728-34.     

 
25

Sharma R, Sundar S. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8. Eur Urol. 2007 Apr;51(4):1146. Epub 2006 Dec 4.     

 
26

Colquhoun AJ, Sundar S, Rajjayabun PH, Griffiths TR, Symonds RP, Mellon JK. Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer. Clin Oncol (R Coll Radiol). 2006 Nov;18(9):702-9.     

 
27

 Khan S, Dhadda A, Fyfe D, Sundar S. Impact of neutropenia on delivering planned chemotherapy for solid tumours. Eur J Cancer Care (Engl). 2008 Jan;17(1):19-25.

 
28

Cox RA, Sundar S. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy. Br J Cancer. 2008 Jan 15;98(1):238-9. 

 
29

Matzinger O, Duclos F, van den Bergh A, Carrie C, Villà S, Kitsios P, Poortmans P, Sundar S, van der Steen-Banasik EM, Gulyban A, Collette L, Bolla M. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC  trial 22991. Eur J Cancer.2009 Nov;45(16):2825-34.

 
30

Sundar.S. Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol. 2011 Dec;60(6):e51. Epub 2011 Sep 17

 
31

Mishra N, Petrovic S, Sundar S. A self-adaptive case-based reasoning system for dose planning in prostate cancer radiotherapy. Med Phys. 2011 Dec;38(12):6528.

 

32
Perry CJ, Sundar S. Cabazitaxel Rechallenge at Prostate-Specific Antigen Relapse After Previous Cabazitaxel and Docetaxel Chemotherapy: Clin Genitourin Cancer. 2012 Mar 23
33

Ho JW, Sundar S . Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake? . Clin Genitourin Cancer. 2012 Mar;10(1):50-3. Epub 2012 Jan 14.

 
34

Sundar S, Dickinson PD. Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ Case Reports 2012;10.1136/bcr.11.2011.5238

 
35 Pascoe AC, Sundar S. Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer. Radiat Oncol. 2012 Mar 22;7(1):43.  
36

Dickinson PD, Peel DN, Sundar S. Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate. Br J Cancer. 2012 Apr 10;106(8):1464-5. doi: 10.1038/bjc.2012.78. Epub 2012 Mar 13.

 
37 Sundar S. Sugar-free medicines are counterproductive. Br Dent J. 2012 Sep 7;213(5):207-8. doi: 10.1038/sj.bdj.2012.777.  
38 Dickinson P, Sundar S. Salvage radiotherapy after high intensity focused ultrasound for prostate cancer. BMJ Case Reports June 2012 (10.1136/bcr.03.2012.6127).  
39 Dickinson, P.D, Chan, S.Y, Sundar, S. The Clinical Usefulness of DNA Aneuploidy in Borderline Ovarian Tumours. Onkologie 2012;35:607 (DOI:10.1159/000343264)  
40 Sundar S. The return of the snake oil salesmen: the sequel. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):571. doi: 10.1016/j.ijrobp.2012.06.016